108606009: Salmeterol xinafoate (substance)

SNOMED CT Concept\Substance\...

\Substance categorized by disposition\Receptor agonist\Adrenergic receptor agonist\Beta adrenergic receptor agonist\Substance with beta-2 adrenergic receptor agonist mechanism of action (substance)\Salmeterol xinafoate

\A grouper concept for substances that are used in medicinal products for medical treatment, and also psychoactive substances that have few or no legitimate medical uses or that are not legally available to the person using them.\Autonomic agent (substance)\Sympathomimetic agent (substance)\Adrenergic receptor agonist\Beta adrenergic receptor agonist\Substance with beta-2 adrenergic receptor agonist mechanism of action (substance)\Salmeterol xinafoate
\A grouper concept for substances that are used in medicinal products for medical treatment, and also psychoactive substances that have few or no legitimate medical uses or that are not legally available to the person using them.\Respiratory system agent (substance)\Bronchodilator (substance)\Substance with beta-2 adrenergic receptor agonist mechanism of action (substance)\Salmeterol xinafoate

\Substance categorised by structure\Chemical\Chemical categorized by structure (substance)\Organic compound\Organic cyclic compound\Substance with phenol structure\Salmeterol xinafoate

Status: current, Not sufficiently defined by necessary conditions definition status (core metadata concept). Date: 31-Jan 2002. Module: SNOMED CT core

Descriptions:

Id Description Lang Type Status Case? Module

173140019 Salmeterol xinafoate en Synonym (core metadata concept) Active Entire term case insensitive (core metadata concept) SNOMED CT core

602650010 Salmeterol xinafoate (substance) en Fully specified name Active Entire term case insensitive (core metadata concept) SNOMED CT core

28121000188110 salmétérol xinafoate fr Synonym (core metadata concept) Active Entire term case insensitive (core metadata concept) SNOMED CT Switzerland NRC maintained Module

839291000172113 xinafoate de salmétérol fr Synonym (core metadata concept) Active Entire term case insensitive (core metadata concept) SNOMED CT Switzerland NRC maintained Module

Expanded Value Set

Outbound Relationships	Type	Target	Active	Characteristic	Refinability	Group	Values
Salmeterol xinafoate	Is a	Product containing salmeterol (medicinal product)	false	Inferred relationship	Some
Salmeterol xinafoate	Is a	Salmeterol (substance)	false	Inferred relationship	Some
Salmeterol xinafoate	This attribute specifies the behavior that a substance will exhibit or participate in, given the appropriate context.	Beta adrenergic receptor agonist (disposition)	false	Inferred relationship	Some
Salmeterol xinafoate	This attribute specifies the behavior that a substance will exhibit or participate in, given the appropriate context.	Beta-2 adrenergic receptor agonist	true	Inferred relationship	Some
Salmeterol xinafoate	This attribute indicates that the concept is a structural modification of another concept, and that the substance's intrinsic physicochemical properties remain unchanged.	Salmeterol (substance)	true	Inferred relationship	Some
Salmeterol xinafoate	Is a	Substance with beta-2 adrenergic receptor agonist mechanism of action (substance)	true	Inferred relationship	Some
Salmeterol xinafoate	Is a	Substance with phenol structure	true	Inferred relationship	Some

Inbound Relationships	Type	Active	Source	Characteristic	Refinability	Group
Salmeterol xinafoate 21mcg/spray aerosol	The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications.	False	Salmeterol xinafoate	Inferred relationship	Some
Salmeterol xinafoate 50mcg powder	The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications.	False	Salmeterol xinafoate	Inferred relationship	Some
Salmeterol xinafoate 38.06mcg inhalant	The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications.	False	Salmeterol xinafoate	Inferred relationship	Some
Product containing fluticasone and salmeterol (medicinal product)	The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications.	False	Salmeterol xinafoate	Inferred relationship	Some
Fluticasone propionate + salmeterol xinafoate 250mcg/50mcg powder for oral inhalation	The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications.	False	Salmeterol xinafoate	Inferred relationship	Some
Fluticasone propionate + salmeterol xinafoate 500mcg/50mcg powder for oral inhalation	The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications.	False	Salmeterol xinafoate	Inferred relationship	Some
Fluticasone propionate + salmeterol xinafoate 100mcg/50mcg powder for oral inhalation (product)	The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications.	False	Salmeterol xinafoate	Inferred relationship	Some
Salmeterol+fluticasone propionate 50micrograms/100micrograms breath-actuated dry powder inhaler	The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications.	False	Salmeterol xinafoate	Inferred relationship	Some
Salmeterol+fluticasone propionate 25micrograms/250micrograms CFC-free inhaler	The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications.	False	Salmeterol xinafoate	Inferred relationship	Some
Salmeterol+fluticasone propionate 25micrograms/50micrograms CFC-free inhaler	The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications.	False	Salmeterol xinafoate	Inferred relationship	Some
Salmeterol+fluticasone propionate 50micrograms/500micrograms breath-actuated dry powder inhaler	The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications.	False	Salmeterol xinafoate	Inferred relationship	Some
Salmeterol+fluticasone propionate 25micrograms/125micrograms CFC-free inhaler	The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications.	False	Salmeterol xinafoate	Inferred relationship	Some
Salmeterol+fluticasone propionate 50micrograms/250micrograms breath-actuated dry powder inhaler	The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications.	False	Salmeterol xinafoate	Inferred relationship	Some
Salmeterol (as salmeterol xinafoate) 25 microgram/actuation pressurized suspension for inhalation	The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration).	True	Salmeterol xinafoate	Inferred relationship	Some	1
Salmeterol (as salmeterol xinafoate) 50 microgram/actuation powder for inhalation	The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration).	True	Salmeterol xinafoate	Inferred relationship	Some	1
Fluticasone propionate 50 microgram and salmeterol (as salmeterol xinafoate) 25 microgram/actuation pressurized suspension for inhalation	The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration).	False	Salmeterol xinafoate	Inferred relationship	Some	2
Fluticasone propionate 100 microgram and salmeterol (as salmeterol xinafoate) 50 microgram/actuation powder for inhalation	The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration).	True	Salmeterol xinafoate	Inferred relationship	Some	1
Fluticasone propionate 500 microgram and salmeterol (as salmeterol xinafoate) 50 microgram/actuation powder for inhalation	The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration).	True	Salmeterol xinafoate	Inferred relationship	Some	1
Fluticasone propionate 250 microgram and salmeterol (as salmeterol xinafoate) 25 microgram/actuation pressurized suspension for inhalation	The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration).	True	Salmeterol xinafoate	Inferred relationship	Some	1
Fluticasone propionate 125 microgram and salmeterol (as salmeterol xinafoate) 25 microgram/actuation pressurized suspension for inhalation	The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration).	True	Salmeterol xinafoate	Inferred relationship	Some	1
Fluticasone propionate 250 microgram and salmeterol (as salmeterol xinafoate) 50 microgram/actuation powder for inhalation	The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration).	True	Salmeterol xinafoate	Inferred relationship	Some	1
Product containing precisely salmeterol (as salmeterol xinafoate) 21 microgram/1 actuation conventional release solution for inhalation (clinical drug)	The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration).	True	Salmeterol xinafoate	Inferred relationship	Some	1
Fluticasone propionate 50 microgram and salmeterol (as salmeterol xinafoate) 25 microgram/actuation pressurized suspension for inhalation	The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration).	True	Salmeterol xinafoate	Inferred relationship	Some	1

This concept is not in any reference sets

Back to Start

Id	Description	Lang	Type	Status	Case?	Module
173140019	Salmeterol xinafoate	en	Synonym (core metadata concept)	Active	Entire term case insensitive (core metadata concept)	SNOMED CT core
602650010	Salmeterol xinafoate (substance)	en	Fully specified name	Active	Entire term case insensitive (core metadata concept)	SNOMED CT core
28121000188110	salmétérol xinafoate	fr	Synonym (core metadata concept)	Active	Entire term case insensitive (core metadata concept)	SNOMED CT Switzerland NRC maintained Module
839291000172113	xinafoate de salmétérol	fr	Synonym (core metadata concept)	Active	Entire term case insensitive (core metadata concept)	SNOMED CT Switzerland NRC maintained Module